Diphencyprone – 5 g

Brand:
Cayman
CAS:
886-38-4
Storage:
-20
UN-No:
Non-Hazardous - /

Diphencyprone (DCP) is a contact sensitizing agent.{42859,42860,42861} Pretreatment with DCP reduces symptom severity in a mouse model of experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein (1-10) (MBP1-10).{42859} It enhances IL-10 production and antigen-specific IgG2a antibody responses and reduces anaphylaxis and asthma induced by ovalbumin in mice when administered during ovalbumin immunization at a concentration of 1% v/v.{42860} Topical administration of DCP increases intrafollicular CD4+ and CD8+ T cells, reduces upper dermal inflammation, and stimulates hair growth in the C3H/HeJ mouse model of alopecia areta.{42861} Formulations containing DCP have been used in the treatment of alopecia areta.  

 

Available on backorder

SKU: 27982 - 5 g Category:

Description

A contact sensitizing agent; pretreatment reduces symptom severity in a mouse model of MBP1-10-induced EAE; enhances IL-10 production and antigen-specific IgG2a antibody responses and reduces anaphylaxis and asthma induced by ovalbumin in mice at 1% v/v; topical administration increases intrafollicular CD4+ and CD8+ T cells, reduces upper dermal inflammation, and stimulates hair growth in the C3H/HeJ mouse model of alopecia areta,


Formal name: 2,3-diphenyl-2-cyclopropen-1-one

Synonyms:  Diphenylcyclopropenone|DPC|NSC 57541

Molecular weight: 206.2

CAS: 886-38-4

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Immunotherapeutics||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma